|Bid||80.06 x 1100|
|Ask||81.90 x 900|
|Day's Range||80.28 - 81.45|
|52 Week Range||74.79 - 91.45|
|Beta (5Y Monthly)||0.68|
|PE Ratio (TTM)||39.04|
|Earnings Date||Jul 28, 2021 - Aug 02, 2021|
|Forward Dividend & Yield||1.12 (1.28%)|
|Ex-Dividend Date||Jun 03, 2021|
|1y Target Est||94.00|
DEERFIELD, Ill., Jun 15, 2021--Baxter International Inc. (NYSE:BAX), a leading global medical products company, will host a conference call to discuss its second-quarter 2021 financial results on Thursday, July 29, 2021 at 7:30 a.m. Central Time. To participate in this conference call please follow this link http://www.directeventreg.com/registration/event/8371319 to pre-register for the call and receive the call information.
Baxter's (BAX) Theranova-enabled HDx therapy is likely to boost clinical outcomes and lower healthcare resource utilization.
Baxter International Inc. (NYSE:BAX), a global innovator in renal care, announced today new data showing expanded hemodialysis (HDx) therapy enabled by the Theranova dialyzer may reduce cardiovascular events by 35% and hospitalization rates by 18% according to a new, large, multicenter, retrospective study of Colombian dialysis patients treated with long-term HDx compared to propensity-matched patients treated with High-Flux Hemodialysis.1 The study "Effectiveness of medium cut-off versus high f